Biocon Receives Health Canada Approval of Bosaya (Denosumab) and Vevzuo (Denosumab), Biosimilars to Prolia and Xgeva

Image for article Biocon Receives Health Canada Approval of Bosaya (Denosumab) and Vevzuo (Denosumab), Biosimilars to Prolia and Xgeva
News Source : Financial Post

News Summary

  • Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.
  • The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, demonstrating that BOSAYA and VEVZUO are highly similar to PROLIA and XGEVA, respectively, with no clinically meaningful differences in quality, safety, or efficacy.
  • To report SUSPECTED ADVERSE REACTIONS, contact Biocon at 1-833-986-1468.
Please refer to full Product Monograph for BOSAYA and VEVZUO for more information.To report SUSPECTED ADVERSE REACTIONS, contact Biocon at 18339861468.Biocon Limited (BSE 532523, NSE BIOCON) [+3422 chars]

Must read Articles